FOR IMMEDIATE RELEASE

Contact: marketing@cojourney.com
Date: May 6, 2025
ASGCT Booth: #449

CoJourney CEO to Present Analytical Development in Quantification of Residual Host-Cell E1A DNA at ASGCT 2025

New Orleans, LA – May 17, 2025 – CoJourney is proud to announce that its CEO, **Lijun Wang**, will deliver an oral presentation at the **28th Annual Meeting of ASGCT**.

Presentation Details:

- **Title:** Quantification of Residual Host-Cell DNA Fragments of the E1A Gene from HEK293 via qPCR Assay
- **Room Number:** 388-390
- **Date:** Saturday, May 17, 2025
- **Time:** 8:00 AM – 9:45 AM

The Importance of Residual Host-Cell DNA Quantification

In viral vector manufacturing for gene therapy using HEK293 cells, residual host-cell DNA—especially fragments containing oncogenic sequences such as the E1A gene—poses potential safety risks to patients. CoJourney addresses this challenge with a highly sensitive and specific qPCR assay targeting *E1A,* enabling precise detection and quantification of these residual DNA fragments. This advanced analytical solution provides two key benefits ensuring compliance with safety standards and regulatory requirements: (1) accurate measurement of both quantity and size distribution of residual DNA for drug product, and (2) data-driven optimization of production and purification processes.

Attendees will gain insights into:

- Development and quantification of qPCR assays for residual DNA detection
- Strategies for minimizing residual host-cell DNA in final products
- The role of rigorous quality control in product and process development to ensure patient safety

About CoJourney

CoJourney is a leading CDMO powering the next generation of CGT therapies with cutting-edge plasmid DNA and viral vector manufacturing. Our proprietary Zero Chrom® Platform and scalable rAAV production technology deliver high-yield, cost-effective, and fully compliant solutions, accelerating your drug development journey from discovery to market. CoJourney has secured U.S. and China IND approvals for multiple clients, proving our global regulatory expertise in cell and gene therapies.

Meet the Speaker: Lijun Wang

Lijun Wang is a seasoned process engineer and accomplished entrepreneur specializing in gene therapy viral vector and plasmid manufacturing. With over 20 years of expertise in CGT process development, manufacturing, and CMC regulatory strategy, she founded **CoJourney** to drive process innovation and revolution in scalable, cost-effective platform manufacturing technologies, to ensure broader patient access.

For more information or to schedule a meeting with Lijun Wang during ASGCT 2025, please contact **bd@cojourney.com**. Or **come and visit our booth #449** to meet Lijun and Cojourney team.

#ASGCT2025 #GeneTherapy #CellTherapy #qPCR #HEK293 #ResidualDNA #Plasmid #ViralVectors #BiotechInnovation #CoJourney #CDMO